ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0003725 | Arthropod-borne viruses. A non-taxonomic designation for viruses that can replicate in both vertebrate hosts and arthropod vectors. Included are some members of the following families: ARENAVIRIDAE; BUNYAVIRIDAE; REOVIRIDAE; TOGAVIRIDAE; and FLAVIVIRIDAE. (From Dictionary of Microbiology and Molecular Biology, 2nd ed) | Arbovirus (navigational concept)|arbovirus|Arboviruses|Arthropod-borne Virus|Viruses, Arthropod-Borne|ARBOVIRUS|arboviruses|Arbovirus|Arthropod Borne Viruses|Virus, Arthropod-Borne|Arbovirus, NOS|Arthropod-Borne Viruses|Arthropod-Borne Virus | Arboviruses |
C0039258 | null | Tahyna virus (organism)|Tahyna virus | Tahyna virus |
C0318627 | null | Eyach virus|Eyach virus (organism) | Eyach virus |
C0012634 | A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown. | Disease|Clinical disease or syndrome|Clinical disease or syndrome present, NOS|disorder|Disorders|Disease or syndrome present|disease|Diseases and Disorders|Clinical disease AND/OR syndrome present|condition|Diseases|Disease or syndrome present, NOS|Disorder, NOS|Other Disease|Clinical disease or syndrome, NOS|Disease AND/OR syndrome present|Disease or Disorder, Non-Neoplastic|Disease (disorder)|disorders|Clinical disease AND/OR syndrome|Disorder|Disease or Disorder|Clinical disease or syndrome present|diseases|disease/disorder|Disease, NOS | Disease |
C0042776 | Minute infectious agents whose genomes are composed of DNA or RNA, but not both. They are characterized by a lack of independent metabolism and the inability to replicate outside living host cells. | Virus|Virus, NOS|Viruses, General|Virus (organism)|Vira|Viridae|VIRUSES|viruses|Viruses|viridae|virus|VIRUS | Virus |
C0999630 | null | Lepus capensis|Lepus capensis (organism)|Cape hare|Brown hare | Lepus capensis (organism) |
C0242210 | General term for proteins that have binding as a major function. | Ligand Binding Protein|Binding Protein|binding proteins|binding protein|Proteins, Binding|Protein, Binding|Binding protein (substance)|Binding protein | Binding Proteins |
C0053075 | null | null | beidellite |
C0053075 | null | null | beidellite |
C0242210 | General term for proteins that have binding as a major function. | Ligand Binding Protein|Binding Protein|binding proteins|binding protein|Proteins, Binding|Protein, Binding|Binding protein (substance)|Binding protein | Binding Proteins |
C0004611 | One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. | Unknown eubacteria|Bacterium sp.|unidentified bacterium|bacteria|eubacteria|Eubacteria|Bacteria|unidentified bacteria|unclassified bacterium|Superkingdom Bacteria|Bacteria bacterium|Bacterium, NOS|Domain Bacteria (organism)|Domain Bacteria|BACTERIA|Bacteria, Eubacteria|Bacteria, NOS|Bacterium|Unknown eubacterium|Bacterial sp.|Bacterium (organism)|Bacteria sp.|unknown bacteria|unidentified eubacterium|Bacteria <prokaryotes>|bacterium | Bacteria |
C0031516 | Chemical substances, excreted by an organism into the environment, that elicit behavioral or physiological responses from other organisms of the same species. Perception of these chemical signals may be olfactory or by contact. | pheromones|Recognition odour|Recognition odor|Scent|scent|Pheromone|pheromone|scented|scents|Pheromones|Recognition odor (finding) | Pheromone |
C1167395 | Any organism in which another organism, especially a parasite or symbiont, spends part or all of its life cycle and from which it obtains nourishment and/or protection. [ISBN:0198506732] | hosts|host organism|host|Host | Host (organism) |
C0162318 | null | Farm Animal|Animals, Farm|Animal, Farm|Farm Animals|farm animal|animals farm|animal farm|farm animals | Farm Animals |
C0087111 | Procedures concerned with the remedial treatment or prevention of diseases. | treatment method|methods treatment|treatment|Therapeutics|TX|Therapeutic Method|therapeutic procedure|method treatment|Therapeutic procedure (procedure)|therapeutic method|Treatment|Therapy (regime/therapy)|therapy|Therapy, NOS|therapeutic intervention|Therapeutic Interventions|Procedure - therapeutic|Therapeutic Technique|Therapeutic procedure, NOS|Therapeutic procedure|therapeutics|treatments|therapies|Therapy|Treatments|Therapeutic|Therapeutic Procedure|Therapies|TREAT | Therapeutic procedure |
C0059374 | A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice. | Enrofloxacin|Enrofloxacin-containing product|Product containing enrofloxacin (medicinal product)|enrofloxacin|ENROFLOXACIN|3-Quinolinecarboxylic acid, 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-|1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolonecarboxylic acid|Endrofloxicin|Enrofloxacin (substance) | enrofloxacin |
C0180153 | An object designed to conceal, enclose, cap, or protect something. | coverings|Cover Device|cover [device]|cover|covering|covers|Cover | Covers (device) |
C0004927 | The observable response of a man or animal to a situation. | behavioural response to stimulus|Behavior finding|conducts|Behaviour, NOS|Finding relating to behaviour|Behavioural finding|Behavioral|Behavior|Behavioral finding|Behavior, NOS|Conduct|Behaviour finding|Behaviors|Conation|behavior|conduct|conducting|behavioral response to stimulus|Behavior finding (finding)|behaviour|Conation, NOS|comportment|conation|Conduct, NOS|BEHAVIOR|behaviors|Finding relating to behavior | Behavior |
C0015967 | An abnormal elevation of body temperature, usually as a result of a pathologic process. | Body temperature above reference range (finding)|Fever, unspecified|Elevated Core Body Temperature|raised temperature|TEMPERATURE ELEVATION|Fever|Fever (finding)|feverish|Has a temperature|hyperthermia|Increased body temperature|fever|Body temperature, increased|Febrile|BODY TEMPERATURE INCREASED|temperature elevation|pyrexial|Hyperthermias|hyperthermic|Pyrexial|febris|high body temperature|High body temperature|TEMPERATURE INCREASE|HYPERTHERMIA|Feverish|increase temperature|elevated temperature|Fever NOS|Hyperthermic|FEVER|PYREXIA|high temperature|increased body temperature|fevers|Pyrexia|febrile|Temperature elevated|Pyrexia NOS|Temperature raised|Body temperature above reference range|pyrexia|Pyrexias|temperature increase|Fevers|fevered|increases temperature|Hyperthermia | Fever |
C0012931 | Biologically active DNA which has been formed by the in vitro joining of segments of DNA from different sources. It includes the recombination joint or edge of a heteroduplex region where two recombining DNA molecules are connected. | Recombinant deoxyribonucleic acid (substance)|dna recombinant|Recombinant DNA|recombinant dna|Recombinant deoxyribonucleic acid|rDNA|DNA Construct|Construct|DNA, Recombinant|recombinant DNA|Molecular Biology, Recombinant DNA|rdna | Recombinant DNA |
C0162699 | null | Tick-Borne Infection|Infections, Tick Borne|Tick Borne Infections|Infection, Tick-Borne|Infections, Tick-Borne | Tick-Borne Infections |
C0017677 | An idiopathic disorder of the tongue characterized by the loss of filiform papillae leaving reddened areas of circinate macules bound by a white band. The lesions heal, then others erupt. | lingua geographica|Lingual geographica|tongue geographic|Oral erythema migrans|Glossitis areata migrans|benign migratory glossitis|Glossitis, Benign Migratory|Geographical tongue|lingual geographica|Erythema Migrans, Lingual|TONGUE GEOGRAPHIC|GLOSSITIS, BENIGN MIGRATORY|Psoriasiform mucositis|Geographic Tongue|erythema migran|erythema migrans|geographic tongue|Lingual erythema migrans|Geographic tongue|Lingual Erythema Migrans|Geographic tongue (disorder)|migratory benign glossitis|Migratory Glossitis, Benign|Tongue, Geographic|Glossitis areata exfoliativa|geographical tongue|Benign migratory glossitis|Glossitis Areata Exfoliativa|Benign Migratory Glossitis|Denuded islands on tongue|Benign migrating glossitis|TONGUE, GEOGRAPHIC | Glossitis, Benign Migratory |
C1457887 | An indication that a person has a condition or disease. Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain. | SYMPTOM|Symptoms|Symptom|SYMPTOMS|general manifestation of disorders|symptom|Symptom, NOS | Symptoms |
C0024198 | An infectious disease caused by a spirochete, BORRELIA BURGDORFERI, which is transmitted chiefly by Ixodes dammini (see IXODES) and pacificus ticks in the United States and Ixodes ricinis (see IXODES) in Europe. It is a disease with early and late cutaneous manifestations plus involvement of the nervous system, heart, eye, and joints in variable combinations. The disease was formerly known as Lyme arthritis and first discovered at Old Lyme, Connecticut. | Lyme disease|Steere's disease|B. burgdorferi Infection|Infection due to Borrelia burgdorferi sensu lato|borrelia burgdorferi infection|lyme's disease|Lyme Disease|Lyme disease (disorder)|B. burgdorferi Infections|LYME DISEASE|Disease, Lyme|Infection by Borrelia burgdorferi|Borrelia burgdorferi Infection|Lyme borreliosis|lymes disease|lyme borreliosis|Borrelia Burgdorferi Infection|Borrelia|Borrelia burgdorferi Infections|Borreliosis, Lyme|LYME DISEASE, EARLY/MID|Lyme Borreliosis | Lyme Disease |
C0011900 | The determination of the nature of a disease or condition, or the distinguishing of one disease or condition from another. Assessment may be made through physical examination, laboratory tests, or the likes. Computerized programs may be used to enhance the decision-making process. | diagnosis (DX)|Diagnoses|diagnose|diagnosing|Diagnostic|Diagnosed|Diagnosis (observable entity)|DIAGNOSIS|diagnoses|diagnosed|Dx|Diagnosis|diagnosis | Diagnosis |
C0079603 | null | immunofluorescence|Immunofluorescence|Immunofluorescence assay|Fluorescent immunoassay (procedure)|Immunofluorescence assay, NOS|immunofluorescence assay|assays immunofluorescence|Immunofluorescence technique|Fluorescent linked immunoassay|IF - Immunofluorescence|Fluorescent immunoassay (qualifier value)|IMF - Immunofluorescence|Fluorescent immunoassay|IMF assay|Fluorescent immunoassay, NOS | Immunofluorescence assay |
C0743841 | null | Febrile illness (fever)|Febrile disorder (disorder)|Disorder characterised by fever|Febrile syndrome|Febrile disorder|Febrile illness|febrile illness | Disorder characterized by fever |
C0638611 | null | 1H-Pyrrole-2-carboxylic acid, 4,5-dibromo-|4,5-dibromo-2-pyrrolic acid|DBPA | 4,5-dibromo-2-pyrrolic acid |
C0027895 | Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells. | neuropeptide|Neuropeptide|neuropeptides|Neuropeptides | Neuropeptides |
C1504598 | null | null | Crosstalk - device related injury/complication |
C0024852 | An infraclass of MAMMALS, also called Metatheria, where the young are born at an early stage of development and continue to develop in a pouch (marsupium). In contrast to Eutheria (placentals), marsupials have an incomplete PLACENTA. | Marsupialia|ORDER MARSUPIALIA - MARSUPIALS OR POUCHED MAMMALS|Pouched mammal, NOS|marsupial|marsupials|Marsupials|Metatheria|Marsupial | Superorder Marsupalia (organism) |
C0024852 | An infraclass of MAMMALS, also called Metatheria, where the young are born at an early stage of development and continue to develop in a pouch (marsupium). In contrast to Eutheria (placentals), marsupials have an incomplete PLACENTA. | Marsupialia|ORDER MARSUPIALIA - MARSUPIALS OR POUCHED MAMMALS|Pouched mammal, NOS|marsupial|marsupials|Marsupials|Metatheria|Marsupial | Superorder Marsupalia (organism) |
C0024852 | An infraclass of MAMMALS, also called Metatheria, where the young are born at an early stage of development and continue to develop in a pouch (marsupium). In contrast to Eutheria (placentals), marsupials have an incomplete PLACENTA. | Marsupialia|ORDER MARSUPIALIA - MARSUPIALS OR POUCHED MAMMALS|Pouched mammal, NOS|marsupial|marsupials|Marsupials|Metatheria|Marsupial | Superorder Marsupalia (organism) |
C0024852 | An infraclass of MAMMALS, also called Metatheria, where the young are born at an early stage of development and continue to develop in a pouch (marsupium). In contrast to Eutheria (placentals), marsupials have an incomplete PLACENTA. | Marsupialia|ORDER MARSUPIALIA - MARSUPIALS OR POUCHED MAMMALS|Pouched mammal, NOS|marsupial|marsupials|Marsupials|Metatheria|Marsupial | Superorder Marsupalia (organism) |
C0024660 | Warm-blooded vertebrate animals belonging to the class Mammalia, including all that possess hair and suckle their young. | Mammal|Mammals|Mammalian|Mammalia|CLASS MAMMALIA - MAMMALS|Class Mammalia|mammals|Class Mammalia (organism)|Mammals, General|mammal | Mammals |
C0034850 | Cytoplasmic vesicles formed when COATED VESICLES shed their CLATHRIN coat. Endosomes internalize macromolecules bound by receptors on the cell surface. | endosome|Endosomes|Receptosome|Receptosomes|Endosome | Endosomes |
C0699040 | The external part of the cell wall and/or plasma membrane. [GOC:jl, GOC:mtg_sensu, GOC:sm] | cell bound|Cell Surface|Surface of cell|cell associated|External surface of plasma membrane|cell surface|External surface of plasmam membrane|Cell surface | Cell surface |
C1099354 | Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions. | Short Interfering RNA|Interfering RNA, Small|interfering rnas small|small interfering rna|Interfering RNA, Short|Small interfering RNA|siRNA|RNA, Short Interfering|sirna|RNA, Small Interfering|Small Interfering RNA|small interfering RNA | RNA, Small Interfering |
C0817332 | null | Right calcaneus | Right calcaneus |
C0817332 | null | Right calcaneus | Right calcaneus |
C0817332 | null | Right calcaneus | Right calcaneus |
C0017262 | The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. | Gene expression|gene expression|expression gene|Gene Expression|Expression, Gene|Expressions, Gene|Expression|Expressed|Gene Expressions|Gene expression (finding) | Gene Expression |
C0042896 | Phospholipoglycoproteins produced in the fat body of egg-laying animals such as non-mammalian VERTEBRATES; ARTHROPODS; and others. Vitellogenins are secreted into the HEMOLYMPH, and taken into the OOCYTES by receptor-mediated ENDOCYTOSIS to form the major yolk proteins, VITELLINS. Vitellogenin production is under the regulation of steroid hormones, such as ESTRADIOL and JUVENILE HORMONES in insects. | Vitellogenins|vitellogenin|Vitellogenin | Vitellogenins |
C0042896 | Phospholipoglycoproteins produced in the fat body of egg-laying animals such as non-mammalian VERTEBRATES; ARTHROPODS; and others. Vitellogenins are secreted into the HEMOLYMPH, and taken into the OOCYTES by receptor-mediated ENDOCYTOSIS to form the major yolk proteins, VITELLINS. Vitellogenin production is under the regulation of steroid hormones, such as ESTRADIOL and JUVENILE HORMONES in insects. | Vitellogenins|vitellogenin|Vitellogenin | Vitellogenins |
C1533685 | Administration using positive pressure and a needle or other equipment to drive a substance into the body. | Administration of injection|INJECTIONS|Injection, NOS|Injection - action (qualifier value)|injection|Injection|Injections|Injection Administration|Injection - action|Injection (procedure) | Injection procedure |
C1334043 | A gene from one species which corresponds to a gene in another species and that is related via a common ancestral species. These genes retain a similar sequence and function. | Homolog|Gene Homolog|Homologous|Homologous Gene|Homologous Association|Homologue|Homology | Homologous Gene |
C0751608 | A collection of DNA molecules that have been cloned in vectors. In the case of a cDNA library the DNA inserts are copies of RNAs that have been reverse-transcribed into DNA prior to cloning. | Libraries, cDNA|cDNA Libraries|Library|Library, cDNA|cDNA Library | cDNA Library |
C1281743 | A post-MORULA preimplantation mammalian embryo that develops from a 32-cell stage into a fluid-filled hollow ball of over a hundred cells. A blastocyst has two distinctive tissues. The outer layer of trophoblasts gives rise to extra-embryonic tissues. The inner cell mass gives rise to the embryonic disc and eventual embryo proper. | Embryos, Preimplantation|Blastocyst structure|preimplantation embryos|Blastosphere|blastula stage|Embryo, Preimplantation|Preimplantation Embryos|blastosphere|Blastocyst structure (body structure)|Blastocysts|Preimplantation Embryo|blastula|Blastocyst|blastocysts|Blastula|blastocyst | Blastocyst structure |
C0162788 | A technique that localizes specific nucleic acid sequences within intact chromosomes, eukaryotic cells, or bacterial cells through the use of specific nucleic acid-labeled probes. | In Situ Hybridizations|hybridization in situ|In Situ Hybridization|Hybridization, In Situ|Hybridizations, In Situ|IN SITU HYBRIDIZATION|in situ Hybridization|Genetics, in situ Hybridization|In-situ hybridization|hybridization situ|Hybridization in Situ|in situ hybridization|In situ hybridization|situ hybridization | In Situ Hybridization |
C0013935 | The entities of developing ANIMALS in early stages. | Embryonic|Pantemporal embryo|Embryo|embryo|Embryos|embryonic|Embryo, NOS|embryos | Embryo |
C0021358 | The posterior pair of the quadrigeminal bodies which contain centers for auditory function. | Posterior colliculus|Inferiors, Colliculus|Caudal Colliculus|Testes|Corpus quadrigeminum inferius|Colliculus Inferiors|Colliculus, Inferior|posterior colliculus|Posterior quadrigeminal body|Inferior Colliculi|Corpus bigeminum posterioris|Posterior corpus quadrigeminum|inferior colliculus|Colliculus inferior|Colliculus, Posterior|Posterior Colliculus|Inferior Colliculus|Colliculus caudalis|Posterior Quadrigeminal Body|Inferior, Colliculus|Colliculus Inferior|Structure of inferior colliculus of corpora quadrigemina|Corpus bigeminalis caudalis|Caudal colliculus|Colliculi, Inferior|Corpora quadrigemina, inferior colliculus|Structure of inferior colliculus of corpora quadrigemina (body structure)|Inferior colliculus of corpora quadrigemina|Inferior colliculus|Colliculus, Caudal | Inferior Colliculus |
C0005539 | Application of principles and practices of engineering science to biomedical research and health care. | bioengineering/biomedical engineering|bioengineered|Engineering, Biomedical|bioengineering|biomedical engineering|Biomedical engineering|biomedical engineer|Biomedical Engineering | biomedical engineering field |
C0007634 | The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary. | Cells|Cells set|cell|Cellula|Cell structure|Cell Type|Cell structure (cell structure)|Set of cells|cells|Cell Types|Cell|Normal cell|Normal Cell|Cellular structures|Cell, NOS|The Cell|{Cells}|THE CELL|Cellular structure|the cell|Cellular | Cells |
C0010834 | The part of a cell that contains the CYTOSOL and small structures excluding the CELL NUCLEUS; MITOCHONDRIA; and large VACUOLES. (Glick, Glossary of Biochemistry and Molecular Biology, 1990) | cytoplasma|cytoplasm|Cytoplasm|Cytoplasmic|Cytoplasms|Cytoplasma | Cytoplasm |
C0007610 | Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) | Nucleus, Cell|Nucleus|NUCLEUS|Nucleus, NOS|Nucleic|cell nucleus|Nucleus of cell|Nuclei, Cell|cell nuclei|Nucleus (cell structure)|Cell nucleus|nucleus|Cell Nuclei|Cell nuclei|Cell Nucleus | Cell Nucleus |
C1185738 | Any cylindrical, vertical, upright structure. | Column|Column structure (qualifier value)|column|Column structure | Column (anatomic) |
C0031327 | Dynamic and kinetic mechanisms of exogenous chemical and DRUG LIBERATION; ABSORPTION; BIOLOGICAL TRANSPORT; TISSUE DISTRIBUTION; BIOTRANSFORMATION; elimination; and DRUG TOXICITY as a function of dosage, and rate of METABOLISM. LADMER, ADME and ADMET are abbreviations for liberation, absorption, distribution, metabolism, elimination, and toxicology. | pharmacokinetics|Drug Kinetics|mechanism of action|drug kinetics|PK|Pharmacokinetics|Kinetics, Drug | Drug Kinetics |
C0017973 | Heteropolysaccharides which contain an N-acetylated hexosamine in a characteristic repeating disaccharide unit. The repeating structure of each disaccharide involves alternate 1,4- and 1,3-linkages consisting of either N-acetylglucosamine (see ACETYLGLUCOSAMINE) or N-acetylgalactosamine (see ACETYLGALACTOSAMINE). | Glycosaminoglycan, NOS|mucopolysaccharides|Mucopolysaccharides|Glycosaminoglycan|Glycosaminoglycans|glycosaminoglycans|glycosaminoglycan|Mucopolysaccharide|Mucopolysaccharide, NOS|mucopolysaccharide|GAG|glycosaminoglycan (GAG)|Mucopolysaccharide (substance)|gag(glycosaminoglycan)|GAG - Glycosaminoglycan | Glycosaminoglycans |
C0015350 | A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere. | Matrix, Extracellular|ecm|icm|intercellular matrix|Portion of extracellular matrix|Extracellular Matrix|Extracellular matrix|Intercellular matrix|Extracellular Matrices|Cell-Extracellular Matrix|proteinaceous extracellular matrix|ECM|ICM|Matrices, Extracellular|extracellular matrix | Extracellular Matrix |
C0017346 | DNA sequences that form the coding region for proteins associated with the viral core in retroviruses. gag is short for group-specific antigen. | Gene, gag|gag Gene|GAg gene|Group-Specific Antigen Gene|GAG Gene|GAG|Genes, gag|GAg gene (observable entity)|gag Genes | GAG Gene |
C0013855 | An electrochemical process in which macromolecules or colloidal particles with a net electric charge migrate in a solution under the influence of an electric current. | Electrophoresis measurement|Fractionation, Electrophoretic|electrophorese|Electrophoresis technique|ELECTROPHORESIS|Electrophoresis measurement, NOS|Zone electrophoresis measurement|Electrophoresis|Electrophoreses|electrophoresis|electrophoreses|Zone electrophoresis measurement, NOS|Electrophoresis measurement (procedure)|Electrophoresis technique (qualifier value)|EP - Electrophoresis | Electrophoresis |
C0014442 | Biological molecules that possess catalytic activity. They may occur naturally or be synthetically created. Enzymes are usually proteins, however CATALYTIC RNA and CATALYTIC DNA molecules have also been identified. | enzyme|Enzymes|Enzyme (substance)|enzymes|Enzyme, NOS|Enzyme|Biocatalysts|ENZYMES | Enzymes |
C0220806 | A substance with a defined atomic or molecular structure that results from, or takes part in, reactions involving changes in its structure, composition, or properties. | chemical compounds|Chemical compound, NOS|Chemically|Chemical|Chemical product, NOS|Chemical, NOS|Chemicals|chemical compound|chemical|chemical substance|Chemical (substance)|chemicals | Chemicals |
C0011847 | null | Diabetes | Diabetes |
C1511790 | The activity of perceiving, discerning, discovering or identifying. | Detection|Detected | Detection |
C0004239 | Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES). | atrial flutter|Atrial flutter|FLUTTER ATRIAL|Atrial Flutters|Flutter, Atrial|flutter auricular|Flutter, Auricular|Atrial flutter (disorder)|Flutters, Atrial|Flutters, Auricular|Auricular Flutter|ATRIAL FLUTTER|Atrial Flutter|Auricular Flutters | Atrial Flutter |
C0039234 | Abnormally rapid heartbeats originating from one or more automatic foci (nonsinus pacemakers) in the HEART ATRIUM but away from the SINOATRIAL NODE. Unlike the reentry mechanism, automatic tachycardia speeds up and slows down gradually. The episode is characterized by a HEART RATE between 135 to less than 200 beats per minute and lasting 30 seconds or longer. | Ectopic atrial tachycardia|Tachycardia, Ectopic Atrial|Atrial Tachycardia, Ectopic|Ectopic Tachycardia, Atrial|Ectopic Tachycardias, Atrial|Tachycardias, Atrial Ectopic|Atrial Ectopic Tachycardia|Atrial Tachycardias, Ectopic|Tachycardias, Ectopic Atrial|Tachycardia, Atrial Ectopic|Ectopic atrial tachycardia (disorder)|Ectopic Atrial Tachycardia|Automatic atrial tachycardia|atrial ectopic tachycardia|Atrial Ectopic Tachycardias|Ectopic Atrial Tachycardias|ectopic atrial tachycardia | Tachycardia, Ectopic Atrial |
C0039235 | A rare form of supraventricular tachycardia caused by automatic, not reentrant, conduction initiated from sites at the atrioventricular junction, but not the ATRIOVENTRICULAR NODE. It usually occurs during myocardial infarction, after heart surgery, or in digitalis intoxication with a HEART RATE ranging from 140 to 250 beats per minute. | Ectopic Tachycardia, Junctional|Junctional Tachycardias, Ectopic|His bundle (junctional ectopic) tachycardia|Junctional Ectopic Tachycardias|Tachycardias, Ectopic Junctional|Junctional ectopic tachycardia|junctional tachycardia|Ectopic Junctional Tachycardias|His bundle tachycardia|junctional ectopic tachycardia|Junctional Ectopic Tachycardia|JUNCTIONAL TACHYCARDIA|Junctional ectopic tachycardia (disorder)|Tachycardia, Ectopic Junctional|Tachycardia, Junctional Ectopic|Ectopic Junctional Tachycardia|Ectopic Tachycardias, Junctional|His bundle tachycardia (disorder)|Tachycardias, Junctional Ectopic|Junctional Tachycardia, Ectopic | Tachycardia, Ectopic Junctional |
C0042514 | An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation). | TACHYCARDIA VENTRICULAR|ventricular tachyarrhythmia|Ventricular Tachycardia|Ventricular tachycardia (Vtach)|ventricular tachycardia (V-tach)|Ventricular tachycardia (disorder)|ventricular tachycardia|TACHYCARDIA, VENTRICULAR|Ventricular tachycardia|vt|VT|VENTRICULAR TACHYARRHYTHMIA|Ventricular tachycardia, NOS|Ventricular tachyarrhythmia (disorder)|Ventricular Tachycardias|Tachycardia, ventricular|VENTRICULAR TACHYCARDIA|VT - Ventricular tachycardia|v tach|Tachycardia, Ventricular|Ventricular tachyarrhythmia|Tachycardias, Ventricular | Tachycardia, Ventricular |
C0025741 | An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. | O methyl DOPA|methyldopa (levorotatory)|Methyldopa-containing product|AMD|alpha-Methyldopa|alpha-methyldopa|L-Tyrosine, 3-hydroxy-alpha-methyl-|L-alpha-Methyldopa|Methyldopa (substance)|Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine|(S)-(-)-alpha-Methyldopa|alpha-Methyl dopa|alpha-methyl-L-dopa|Alphamethyldopa|α-methyl-L-dopa|Product containing methyldopa (medicinal product)|METHYLDOPA|3-Hydroxy-alpha-methyl-L-tyrosine|L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic Acid|alpha-Methyl-L-Dopa|metildopa|alpha methyldopa|alpha Methyldopa|methyldopa|alpha Methyl L Dopa|Methyldopa|alphamethyldopa|Methyl dopa|α-Methyl dopa|L-Methyl Dopa|Alpha medopa | methyldopa |
C0025741 | An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. | O methyl DOPA|methyldopa (levorotatory)|Methyldopa-containing product|AMD|alpha-Methyldopa|alpha-methyldopa|L-Tyrosine, 3-hydroxy-alpha-methyl-|L-alpha-Methyldopa|Methyldopa (substance)|Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine|(S)-(-)-alpha-Methyldopa|alpha-Methyl dopa|alpha-methyl-L-dopa|Alphamethyldopa|α-methyl-L-dopa|Product containing methyldopa (medicinal product)|METHYLDOPA|3-Hydroxy-alpha-methyl-L-tyrosine|L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic Acid|alpha-Methyl-L-Dopa|metildopa|alpha methyldopa|alpha Methyldopa|methyldopa|alpha Methyl L Dopa|Methyldopa|alphamethyldopa|Methyl dopa|α-Methyl dopa|L-Methyl Dopa|Alpha medopa | methyldopa |
C0029463 | A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) | Osteosarcoma, NOS|Osteosarcoma - disorder|Osteosarcoma Tumors|Osteosarcoma, no ICD-O subtype|OSTEOSARCOMA|OSTEOGENIC SARCOMA|Tumor, Osteosarcoma|Osteochondrosarcoma|Tumors, Osteosarcoma|bone sarcomas|osteochondrosarcoma|Osteosarcoma|osteosarcomas|osteoid sarcoma|Osteogenic Sarcoma|OSRC|bone sarcoma|OSTEOSARCOMA, MALIGNANT|Osteosarcoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Osteogenic sarcoma, NOS|osteogenic sarcoma|sarcoma, osteogenic|Sarcoma, Osteogenic|Sarcomas, Osteogenic|SARCOMA OSTEOGENIC|Bone cell cancer|osteosarcoma|BONE CANCER, OSTEOGENIC SARCOMA|Osteosarcomas|Osteosarcoma, no International Classification of Diseases for Oncology subtype|Osteogenic Sarcomas|Osteogenic sarcoma|Osteosarcoma Tumor | Osteosarcoma |
C0221002 | Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones. | Primary hyperparathyroidism|HYPERPARATHYROIDISM PRIMARY|primary hyperparathyroidism|Hyperparathyroidism, primary|Hyperparathyroidisms, Primary|Primary Hyperparathyroidisms|Primary Hyperparathyroidism|HYPERPARATHYROIDISM, PRIMARY|Primary hyperparathyroidism (disorder) | Hyperparathyroidism, Primary |
C0006826 | A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Malignant cells can also spread to other parts of the body through the blood and lymph systems. There are several main types of malignancy. Carcinoma is a malignancy that begins in the skin or in tissues that line or cover internal organs. Sarcoma is a malignancy that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a malignancy that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood. Lymphoma and multiple myeloma are malignancies that begin in the cells of the immune system. Central nervous system cancers are malignancies that begin in the tissues of the brain and spinal cord. | malignant neoplasms|malignant neoplasm|Malignant tumor|Malignant neoplasm without specification of site|NEOPLASM MALIGNANT|malignant tumour|malignant tumors|Unclassified tumor, malignant|malignant tumor|neoplasm/cancer|Tumor, malignant, NOS|Unclassified tumour, malignant|Malignant Tumor|Neoplasm, Malignant|Malignant Growth|Malignancy|MALIGNANCIES|Cancer|Neoplasms, Malignant|CA|Malignancy, unspecified site|Cancers|Tumour, malignant|CANCER (NOS)|Tumor, malignant|cancers|cancer|CA - Cancer|Malignant neoplastic disease (disorder)|Malignant Neoplasm|Malignant neoplastic disease|CANCER|MALIGNANCY|Malignant tumour|Neoplastic disease, malignant|MALIGNANT TUMOR|Malignant Neoplastic Disease|malignant tumoral disease|malignant tumours|malignancy|NEOPLASM, MALIGNANT|Neoplasm, malignant|Malignant Neoplasms|Malignant neoplasm|malignancies|Cancer, unspecified site|Malignancies | Malignant Neoplasms |
C0025741 | An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. | O methyl DOPA|methyldopa (levorotatory)|Methyldopa-containing product|AMD|alpha-Methyldopa|alpha-methyldopa|L-Tyrosine, 3-hydroxy-alpha-methyl-|L-alpha-Methyldopa|Methyldopa (substance)|Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine|(S)-(-)-alpha-Methyldopa|alpha-Methyl dopa|alpha-methyl-L-dopa|Alphamethyldopa|α-methyl-L-dopa|Product containing methyldopa (medicinal product)|METHYLDOPA|3-Hydroxy-alpha-methyl-L-tyrosine|L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic Acid|alpha-Methyl-L-Dopa|metildopa|alpha methyldopa|alpha Methyldopa|methyldopa|alpha Methyl L Dopa|Methyldopa|alphamethyldopa|Methyl dopa|α-Methyl dopa|L-Methyl Dopa|Alpha medopa | methyldopa |
C0025741 | An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. | O methyl DOPA|methyldopa (levorotatory)|Methyldopa-containing product|AMD|alpha-Methyldopa|alpha-methyldopa|L-Tyrosine, 3-hydroxy-alpha-methyl-|L-alpha-Methyldopa|Methyldopa (substance)|Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine|(S)-(-)-alpha-Methyldopa|alpha-Methyl dopa|alpha-methyl-L-dopa|Alphamethyldopa|α-methyl-L-dopa|Product containing methyldopa (medicinal product)|METHYLDOPA|3-Hydroxy-alpha-methyl-L-tyrosine|L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic Acid|alpha-Methyl-L-Dopa|metildopa|alpha methyldopa|alpha Methyldopa|methyldopa|alpha Methyl L Dopa|Methyldopa|alphamethyldopa|Methyl dopa|α-Methyl dopa|L-Methyl Dopa|Alpha medopa | methyldopa |
C0699748 | The set of specific processes that generate the ability of an organism to induce an abnormal, generally detrimental state in another organism. [GOC:go_curators] | pathogeneses|Pathogenesis (attribute)|Pathogenesis|Pathogeneses|Pathogeneses (qualifier value)|pathogenesis | Pathogenesis |
C0029456 | Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. | Osteoporosis, unspecified|Bone rarefaction|Osteoporoses|osteoporosis|Osteoporosis (disorder)|OSTEOPOROSIS|Osteoporosis, NOS|Osteoporosis | Osteoporosis |
C0752046 | A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population. | single nucleotide polymorphism|Single Nucleotide Polymorphisms|snp|Polymorphism, Single Base|single nucleotide polymorphisms|Nucleotide Polymorphism, Single|SNP|Polymorphisms, Single Nucleotide|single nucleotide polymorphism (SNP)|Nucleotide Polymorphisms, Single|SNPs|Polymorphism, Single Nucleotide|Single Nucleotide Polymorphism | Single Nucleotide Polymorphism |
C0017337 | A category of nucleic acid sequences that function as units of heredity and which code for the basic instructions for the development, reproduction, and maintenance of organisms. | Gene (substance)|Gene|genes|Genes|GENE|Gene, NOS|gene | Genes |
C1412100 | null | diamine oxidase|AOC1 gene|ABP|DIAMINE OXIDASE|amine oxidase copper containing 1|DAO1|AMILORIDE-BINDING PROTEIN 1|ABP1|AOC1|DAO | AOC1 gene |
C1412100 | null | diamine oxidase|AOC1 gene|ABP|DIAMINE OXIDASE|amine oxidase copper containing 1|DAO1|AMILORIDE-BINDING PROTEIN 1|ABP1|AOC1|DAO | AOC1 gene |
C0524722 | procedures performed on the gastrointestinal system or its parts, used in the treatment of disease, injuries, or deformities; includes excision of a portion of the gastrointestinal system. | Surgical Procedure, Gastrointestinal|Gastrointestinal Surgical Procedures|OR Gastrointestinal Therapeutic Procedure|Procedure, Gastrointestinal Surgical|gastrointestinal surgery|Surgical Procedures, Gastrointestinal|operative procedure on the gastrointestinal system|Procedures, Gastrointestinal Surgical|gastrointestinal surgical procedure|gastrointestinal system operative procedure|gastrointestinal surgeries|Surgery, Gastrointestinal | Gastrointestinal Surgical Procedure |
C0596119 | cell membrane found on the surface of vertebrate epithelial cells which faces the external lumen and may be involved in transport of substances across the cell. | apical membrane | apical membrane |
C0040549 | A poison made by certain bacteria, plants, or animals, including insects. | Toxin, NOS|Toxin|Toxins|Toxins, Biological|Toxin-containing product|toxin|Biological Toxins|Product containing toxin (product)|Toxin (substance)|toxins | Toxin |
C0596902 | Membrane proteins whose primary function is to facilitate the transport of molecules across a biological membrane. Included in this broad category are proteins involved in active transport (BIOLOGICAL TRANSPORT, ACTIVE), facilitated transport and ION CHANNELS. | membrane transport protein|Transport Proteins, Membrane|transporter|transporters|membrane transport proteins|Membrane Transport Proteins|membrane transporter|Membrane Transporters|Transporters, Membrane | Membrane Transport Proteins |
C0001617 | Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation). | adrenal cortical hormone|Adrenal cortex hormone-containing product|Product containing adrenal cortex hormone (product)|Corticosteroids|adrenocorticosteroids|Adrenal cortical hormone-containing product|Adrenal cortical hormone, NOS|Adrenocorticosteroids|Product containing corticosteroid and corticosteroid derivative (product)|adrenal cortex hormones|Therapeutic Corticosteroid|Corticoids|Adrenal Cortex Hormones|corticoids|Corticosteroid|corticosteroids|adrenal corticosteroid|Corticosteroid and corticosteroid derivative-containing product|corticosteroid|Corticoid preparation, NOS|corticoid|Corticoid|adrenal corticosteroids|Adrenal cortical hormone|ADRENAL CORTICOSTERIODS|Adrenal cortex hormone|adrenal cortex hormone|Adrenal cortex hormone (substance)|Hormones, Adrenal Cortex | Adrenal Cortex Hormones |
C0666743 | A chimeric monoclonal antibody to TNF-ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE. | Infliximab-containing product|Infliximab|monoclonal antibody ca2|INFLIXIMAB|Product containing infliximab (medicinal product)|Infliximab (genetical recombination)|infliximab|cA2, Monoclonal Antibody|INFLIX|Monoclonal Antibody cA2|INF|cA2|inFLIXimab|MAb cA2|Infliximab (substance) | infliximab |
C1527392 | agents of both drug and biological origin often used in immunotherapy to stimulate, potentiate, or depress the immune response; also used to inhibit or enhance specific subclasses of immunocytes. | Immunomodulators|Immunomodulator|Immunomodulator-containing product|immunomodulator|Product containing immunomodulator (product)|Substance with immunomodulator mechanism of action|Substance with immunomodulator mechanism of action (substance) | Immunomodulators |
C0199176 | In medicine, action taken to decrease the chance of getting a disease or condition. For example, cancer prevention includes avoiding risk factors (such as smoking, obesity, lack of exercise, and radiation exposure) and increasing protective factors (such as getting regular physical activity, staying at a healthy weight, and having a healthy diet). | Prophylaxis - intent|Prophylaxis, NOS|Preventive procedure (procedure)|Preventive treatment|Prevention|prevention|prophylaxis|PRYLX|PREVENTATIVE|preventive treatment|Prevention Measures|Prophylactic treatment|Prophylaxis - action|Preventive Intervention|Prophylactic treatment, NOS|Preventative treatment|Prophylaxis|Prophylaxis - procedure intent (qualifier value)|prophylactic treatment|preventive intervention|Preventive procedure|Prophylaxis - procedure intent|Preventive treatment, NOS | Prophylactic treatment |
C0086388 | The actions of prevention, treatment, and management of illness and the preservation of mental and physical well-being through the services offered by the medical and allied health professions. | Care, Health|Healthcare Activity|HealthCare|Health Care Activity|Health Care|health care|healthcare|Healthcare | Health Care |
C0030274 | A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM. | Exocrine and endocrine pancreas, NOS|Exocrine and endocrine pancreas|pancreas|Pancreas, NOS|Pancreatico-|Pancreas|pancreatic|Pancreo-|Pancreatic|PANCREAS|Pancreatic structure|Pancreatic structure (body structure)|Gastrointestinal Tract, Pancreas|pancreatico | Pancreas |
C0751973 | The protein complement of an organism coded for by its genome. | Proteome|proteome|Proteomes | Proteome |
C0025859 | A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS. | 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol|METOPROLOL|metoprolol|Metoprolol|2-Propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)-|Product containing metoprolol (medicinal product)|DL-metoprolol|(RS)-Metoprolol|Metoprolol (substance)|Metoprolol-containing product | metoprolol |
C0070166 | A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION. | Methyl 2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno(3,2-c)pyridin-5-yl)acetate|Clopidogrel|Clopidogrel-containing product|clopidogrel|CLOPIDOGREL|Clopidogrelum|Clopidogrel (substance)|Product containing clopidogrel (medicinal product) | clopidogrel |
C0679771 | The application of methods designed to reduce the risk of harm associated with certain behaviors without reduction in frequency of those behaviors. The risk-associated behaviors include ongoing and active addictive behaviors. | Harm Minimization|Reduction, Harm|Minimization, Harm|harm avoidance|harm reduction|harm minimization|HARM AVOIDANCE | Harm Reduction |
C0220908 | Evaluation strategies used to identify risk for conditions, diagnose disease early, and monitor change/progression over time. | screening|health screens|screen|screening health|Screening|Health Screening|Screening procedure (procedure)|Screening Procedures|Screening procedures|GENERAL DISEASE SCREENING PROCEDURES|health screenings|Screening procedure|screening procedures|health screening|Screenings|Screening procedure, NOS|health screen|Health screening | Screening procedure |
C0011854 | A chronic condition characterized by minimal or absent production of insulin by the pancreas. | Type 1 diabetes mellitus|Insulin-Dependent Diabetes Mellitus|Insulin Dependent Diabetes Mellitus 1|Diabetes mellitus type I|Diabetes Mellitus, Insulin-Dependent|Diabetes Mellitus, Sudden Onset|DIABETES MELLITUS, TYPE I|Diabetes mellitus type 1 (disorder)|IDDM|Juvenile-Onset Diabetes Mellitus|diabetes type 1|Insulin Dependent Diabetes Mellitus|JUVENILE-ONSET DIABETES|Diabetes Type 1|Type 1 Diabetes|Insulin-dependent diabetes|Diabetes mellitus, juvenile onset type|Diabetes Mellitus, Type I|Diabetes mellitus, Type 1|Immune Mediated Diabetes|juvenile onset diabetes mellitus|insulin dependent diabetes mellitus|diabetes type i|diabetes mellitus type 1|insulin dependent diabetes|JOD|Insulin-dependent diabetes mellitus (type I)|iddm|DIABETES MELLITUS, INSULIN-DEPENDENT, 1|Type I diabetes mellitus|Diabetes Mellitus, Juvenile Onset|Type I Diabetes|Juvenile diabetes|Diabetes Mellitus, Insulin-Dependent, 1|type 1 diabetes mellitus|Insulin dependent diabetes mellitus|type i diabetes|Diabetes mellitus, insulin-dependent|Diabetes, Juvenile-Onset|Diabetes mellitus, type I|Type I Diabetes Mellitus|DIABETES MELLITUS INSULIN DEPENDENT|DIABETES MELLITUS, INSULIN-DEPENDENT|Sudden-Onset Diabetes Mellitus|Diabetes mellitus Type I|juvenile diabetes mellitus|DIABETES MELLITUS, INSULIN DEPENDENT|IDD|Diabetes Mellitus, Juvenile-Onset|Diabetes, Type 1|Insulin Dependent Diabetes|Insulin-dependent diabetes mellitus|INSULIN-DEPENDENT DIABETES MELLITUS 1|type 1 diabetes|diabetes mellitus type i|type i diabetes mellitus|Diabetes mellitus, growth onset type|Diabetes Mellitus, Insulin Dependent|Diabetes Mellitus, Sudden-Onset|Insulin-Dependent Diabetes Mellitus 1|Diabetes mellitus type 1|Type I diabetes|Diabetes Mellitus, Type 1|Juvenile-Onset Diabetes|jodm|Juvenile Onset Diabetes|Type 1 diabetes|DIABETES MELLITUS (JUVENILE ONSET)|type I diabetes mellitus|Juvenile diabetes mellitus|IDDM1|JUVENILE ONSET DIABETES MELLITUS|juvenile-onset diabetes mellitus|Juvenile Diabetes|Type 1 Diabetes Mellitus|DIABETES MELLITUS, TYPE 1|diabetes, type i | Diabetes Mellitus, Insulin-Dependent |
C0233929 | A discharge of fluid from a living body | Emission, NOS|emission|Emission|Emission (finding)|emissions | Emission - Male genitalia finding |
C0677881 | Anticancer drugs that kill cells, especially cancer cells. | Cytotoxic Therapy|Cytotoxic Chemotherapy|Cytotoxic|cytotoxic chemotherapy | Cytotoxic Chemotherapy |